Mineralys Therapeutics NASDAQ:MLYS said the company's Chief Medical Officer, David Malcom Rodman, completed two related equity transactions on March 17, 2026. Rodman sold 417 shares of common stock at $25.65 per share, resulting in gross proceeds of $10,696. On the same day he exercised options to acquire 417 shares at an exercise price of $15.44, representing a total exercise cost of $6,438.
After those moves, Rodman holds 76,140 shares of Mineralys Therapeutics common stock directly and retains direct ownership of 5,000 stock options. The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan that the insider adopted on October 6, 2025.
Market context at time of sale
At the time of the reported transactions the stock was trading at $25.02. Over the prior week the share price had declined 9.5 percent, while the 12-month performance showed an 81 percent gain. Separately, analysis from InvestingPro noted that MLYS currently appears overvalued relative to its Fair Value and flagged that the platform offers eight additional ProTips for investors seeking deeper examination of the company.
Recent financial and clinical developments
Mineralys reported a fourth-quarter 2025 earnings per share result of -0.4, beating a consensus forecast of -0.94. The better-than-expected EPS was a positive surprise for investors, though the company disclosed higher general and administrative expenses and noted the presence of recent trial results that remain a consideration for stakeholders.
On the regulatory and commercial front, the company is advancing preparations related to lorundrostat, its lead candidate for uncontrolled hypertension. Management has been working on expanded medical communications and early engagement with payers as part of launch planning. Mineralys is also exploring strategic options for its pipeline and commercial prospects, including potential mergers and acquisitions, partnerships, or pursuing an independent launch strategy.
Analyst reaction and price targets
Brokerage analysts have adjusted their views following updates about lorundrostat and the company’s development path. BofA Securities raised its price target to $51.00 from $46.00 and kept a Buy rating, citing progress on clinical development. Stifel reiterated a Buy rating and maintained a $52.00 price target, referencing movement toward commercial preparations after the FDA accepted the company’s New Drug Application. Jefferies took a more cautious stance, lowering its price target to $30 from $42 and maintaining a Hold rating, pointing to unresolved questions about the company’s strategy for lorundrostat.
What the transactions signify and limitations
The insider sale and concurrent option exercise were carried out under a previously established trading plan, which is intended to structure the timing of trades and provide pre-clearance under Rule 10b5-1. Beyond the factual disclosure of the trade, option exercise, and current holdings, no additional conclusions about management intent or future company actions can be drawn from the transactions alone.
Investors should weigh the insider activity alongside the company’s recent EPS beat, rising administrative costs, analyst divergence on price targets, and ongoing clinical and commercial work on lorundrostat when forming an overall view of Mineralys Therapeutics.